Global Antispasmodics Drugs Market
Global Antispasmodics Drugs Market

Antispasmodics Drugs Comprehensive Study by Type (Dicyclomine Hydrochloride, Loperamide Hydrochloride, Others), Route of Administration (Oral, Injectable, Sublingual, Others), Indication (Irritable Bowel Syndrome, Stomach Cramps, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), End User (Hospitals, Homecare, Speciality Centres, Others) Players and Region - Global Market Outlook to 2026

Antispasmodics Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jul 2021 Edition 224 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Antispasmodics Drugs Market Overview:
Antispasmodic drugs relax the smooth muscles of the urinary bladder. By exerting a direct spasmolytic action on the bladder's smooth muscle, antispasmodic drugs have been reported to increase bladder capacity and effectively decrease or eliminate urge incontinence. The adverse-effect profile of antispasmodic drugs is similar to that of anticholinergic agents. These drugs may impair the patient's ability to perform activities requiring mental alertness and physical coordination

Growth Drivers
  • Growing prevalence of irritable bowel syndrome
  • High patient awareness level and improvement in treatment

Roadblocks
  • Product recalls

Opportunities
  • Adoption of the sedentary lifestyle
  • Rising investments by major market players in antispasmodics drugs

Challenges
  • Stringent Regulatory Factors on Pharmaceuticals


Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are Allergan (Ireland), Hikma Pharmaceuticals (United Kingdom), Lannett (United States), Mylan N.V.(United States), Nexus Pharmaceuticals (United States), Akorn Incorporated (United States), Aurobindo Pharma (India), Daiichi Sankyo, Inc (Japan), Fresenius Kabi Ag (Germany) and Shanghai Fosun Pharmaceutical & Co., Ltd (China). Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Antispasmodics Drugs market. Considering Market by Indication, the sub-segment i.e. Irritable Bowel Syndrome will boost the Antispasmodics Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Antispasmodics Drugs market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Antispasmodics Drugs market.

What Can be Explored with the Antispasmodics Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Antispasmodics Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Antispasmodics Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Antispasmodics Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Antispasmodics Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Antispasmodic Drugs, Suppliers of Antispasmodic Drugs, Wholesalers, Distributors and Retailers of Antispasmodic Drugs, Pharmaceutical Companies and Medical Research Companies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Antispasmodics Drugs Market?
The Antispasmodics Drugs market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Antispasmodics Drugs Market?
Top performing companies in the Global Antispasmodics Drugs market are Allergan (Ireland), Hikma Pharmaceuticals (United Kingdom), Lannett (United States), Mylan N.V.(United States), Nexus Pharmaceuticals (United States), Akorn Incorporated (United States), Aurobindo Pharma (India), Daiichi Sankyo, Inc (Japan), Fresenius Kabi Ag (Germany) and Shanghai Fosun Pharmaceutical & Co., Ltd (China), to name a few.

3. What trending factors would impact Antispasmodics Drugs Market growth most?
"Used in the Treatment of Various Indications" is seen as one of major influencing trends for Antispasmodics Drugs Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Type
  • Dicyclomine Hydrochloride
  • Loperamide Hydrochloride
  • Others
By Route of Administration
  • Oral
  • Injectable
  • Sublingual
  • Others

By Indication
  • Irritable Bowel Syndrome
  • Stomach Cramps
  • Others

By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By End User
  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Spain
    • Rest of Europe
  • MEA
    • Saudi Arabia
    • Turkey
    • Israel
    • United Arab Emirates
    • South Africa
    • Rest of Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing prevalence of irritable bowel syndrome
      • 3.2.2. High patient awareness level and improvement in treatment
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Factors on Pharmaceuticals
    • 3.4. Market Trends
      • 3.4.1. Used in the Treatment of Various Indications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antispasmodics Drugs, by Type, Route of Administration, Indication, Distribution Channel, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Antispasmodics Drugs (Value)
      • 5.2.1. Global Antispasmodics Drugs by: Type (Value)
        • 5.2.1.1. Dicyclomine Hydrochloride
        • 5.2.1.2. Loperamide Hydrochloride
        • 5.2.1.3. Others
      • 5.2.2. Global Antispasmodics Drugs by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Injectable
        • 5.2.2.3. Sublingual
        • 5.2.2.4. Others
      • 5.2.3. Global Antispasmodics Drugs by: Indication (Value)
        • 5.2.3.1. Irritable Bowel Syndrome
        • 5.2.3.2. Stomach Cramps
        • 5.2.3.3. Others
      • 5.2.4. Global Antispasmodics Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Online Pharmacy
        • 5.2.4.3. Retail Pharmacy
      • 5.2.5. Global Antispasmodics Drugs by: End User (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Homecare
        • 5.2.5.3. Speciality Centres
        • 5.2.5.4. Others
      • 5.2.6. Global Antispasmodics Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Singapore
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Spain
          • 5.2.6.3.7. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Saudi Arabia
          • 5.2.6.4.2. Turkey
          • 5.2.6.4.3. Israel
          • 5.2.6.4.4. United Arab Emirates
          • 5.2.6.4.5. South Africa
          • 5.2.6.4.6. Rest of Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Antispasmodics Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hikma Pharmaceuticals (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lannett (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan N.V.(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Nexus Pharmaceuticals (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Akorn Incorporated (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Aurobindo Pharma (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Daiichi Sankyo, Inc (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Fresenius Kabi Ag (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Shanghai Fosun Pharmaceutical & Co., Ltd (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antispasmodics Drugs Sale, by Type, Route of Administration, Indication, Distribution Channel, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antispasmodics Drugs (Value)
      • 7.2.1. Global Antispasmodics Drugs by: Type (Value)
        • 7.2.1.1. Dicyclomine Hydrochloride
        • 7.2.1.2. Loperamide Hydrochloride
        • 7.2.1.3. Others
      • 7.2.2. Global Antispasmodics Drugs by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Injectable
        • 7.2.2.3. Sublingual
        • 7.2.2.4. Others
      • 7.2.3. Global Antispasmodics Drugs by: Indication (Value)
        • 7.2.3.1. Irritable Bowel Syndrome
        • 7.2.3.2. Stomach Cramps
        • 7.2.3.3. Others
      • 7.2.4. Global Antispasmodics Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Online Pharmacy
        • 7.2.4.3. Retail Pharmacy
      • 7.2.5. Global Antispasmodics Drugs by: End User (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Homecare
        • 7.2.5.3. Speciality Centres
        • 7.2.5.4. Others
      • 7.2.6. Global Antispasmodics Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Singapore
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Spain
          • 7.2.6.3.7. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Saudi Arabia
          • 7.2.6.4.2. Turkey
          • 7.2.6.4.3. Israel
          • 7.2.6.4.4. United Arab Emirates
          • 7.2.6.4.5. South Africa
          • 7.2.6.4.6. Rest of Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antispasmodics Drugs: by Type(USD Million)
  • Table 2. Antispasmodics Drugs Dicyclomine Hydrochloride , by Region USD Million (2015-2020)
  • Table 3. Antispasmodics Drugs Loperamide Hydrochloride , by Region USD Million (2015-2020)
  • Table 4. Antispasmodics Drugs Others , by Region USD Million (2015-2020)
  • Table 5. Antispasmodics Drugs: by Route of Administration(USD Million)
  • Table 6. Antispasmodics Drugs Oral , by Region USD Million (2015-2020)
  • Table 7. Antispasmodics Drugs Injectable , by Region USD Million (2015-2020)
  • Table 8. Antispasmodics Drugs Sublingual , by Region USD Million (2015-2020)
  • Table 9. Antispasmodics Drugs Others , by Region USD Million (2015-2020)
  • Table 10. Antispasmodics Drugs: by Indication(USD Million)
  • Table 11. Antispasmodics Drugs Irritable Bowel Syndrome , by Region USD Million (2015-2020)
  • Table 12. Antispasmodics Drugs Stomach Cramps , by Region USD Million (2015-2020)
  • Table 13. Antispasmodics Drugs Others , by Region USD Million (2015-2020)
  • Table 14. Antispasmodics Drugs: by Distribution Channel(USD Million)
  • Table 15. Antispasmodics Drugs Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 16. Antispasmodics Drugs Online Pharmacy , by Region USD Million (2015-2020)
  • Table 17. Antispasmodics Drugs Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 18. Antispasmodics Drugs: by End User(USD Million)
  • Table 19. Antispasmodics Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 20. Antispasmodics Drugs Homecare , by Region USD Million (2015-2020)
  • Table 21. Antispasmodics Drugs Speciality Centres , by Region USD Million (2015-2020)
  • Table 22. Antispasmodics Drugs Others , by Region USD Million (2015-2020)
  • Table 23. South America Antispasmodics Drugs, by Country USD Million (2015-2020)
  • Table 24. South America Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 25. South America Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 26. South America Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 27. South America Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 28. South America Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 29. Brazil Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 30. Brazil Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 31. Brazil Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 32. Brazil Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 33. Brazil Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 34. Argentina Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 35. Argentina Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 36. Argentina Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 37. Argentina Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 38. Argentina Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 39. Rest of South America Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 40. Rest of South America Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 41. Rest of South America Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 42. Rest of South America Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 43. Rest of South America Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 44. Asia Pacific Antispasmodics Drugs, by Country USD Million (2015-2020)
  • Table 45. Asia Pacific Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 46. Asia Pacific Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 47. Asia Pacific Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 48. Asia Pacific Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 49. Asia Pacific Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 50. China Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 51. China Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 52. China Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 53. China Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 54. China Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 55. Japan Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 56. Japan Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 57. Japan Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 58. Japan Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 59. Japan Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 60. India Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 61. India Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 62. India Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 63. India Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 64. India Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 65. South Korea Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 66. South Korea Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 67. South Korea Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 68. South Korea Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 69. South Korea Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 70. Singapore Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 71. Singapore Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 72. Singapore Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 73. Singapore Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 74. Singapore Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 75. Australia Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 76. Australia Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 77. Australia Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 78. Australia Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 79. Australia Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 85. Europe Antispasmodics Drugs, by Country USD Million (2015-2020)
  • Table 86. Europe Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 87. Europe Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 88. Europe Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 89. Europe Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 90. Europe Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 91. Germany Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 92. Germany Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 93. Germany Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 94. Germany Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 95. Germany Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 96. France Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 97. France Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 98. France Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 99. France Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 100. France Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 101. Italy Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 102. Italy Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 103. Italy Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 104. Italy Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 105. Italy Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 106. United Kingdom Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 107. United Kingdom Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 108. United Kingdom Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 109. United Kingdom Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 110. United Kingdom Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 111. Netherlands Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 112. Netherlands Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 113. Netherlands Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 114. Netherlands Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 115. Netherlands Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 116. Spain Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 117. Spain Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 118. Spain Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 119. Spain Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 120. Spain Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 121. Rest of Europe Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 122. Rest of Europe Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 123. Rest of Europe Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 124. Rest of Europe Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 125. Rest of Europe Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 126. MEA Antispasmodics Drugs, by Country USD Million (2015-2020)
  • Table 127. MEA Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 128. MEA Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 129. MEA Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 130. MEA Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 131. MEA Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 132. Saudi Arabia Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 133. Saudi Arabia Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 134. Saudi Arabia Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 135. Saudi Arabia Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 136. Saudi Arabia Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 137. Turkey Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 138. Turkey Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 139. Turkey Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 140. Turkey Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 141. Turkey Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 142. Israel Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 143. Israel Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 144. Israel Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 145. Israel Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 146. Israel Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 147. United Arab Emirates Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 148. United Arab Emirates Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 149. United Arab Emirates Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 150. United Arab Emirates Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 151. United Arab Emirates Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 152. South Africa Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 153. South Africa Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 154. South Africa Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 155. South Africa Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 156. South Africa Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 157. Rest of Africa Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 158. Rest of Africa Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 159. Rest of Africa Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 160. Rest of Africa Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 161. Rest of Africa Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 162. North America Antispasmodics Drugs, by Country USD Million (2015-2020)
  • Table 163. North America Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 164. North America Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 165. North America Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 166. North America Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 167. North America Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 168. United States Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 169. United States Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 170. United States Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 171. United States Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 172. United States Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 173. Canada Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 174. Canada Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 175. Canada Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 176. Canada Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 177. Canada Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 178. Mexico Antispasmodics Drugs, by Type USD Million (2015-2020)
  • Table 179. Mexico Antispasmodics Drugs, by Route of Administration USD Million (2015-2020)
  • Table 180. Mexico Antispasmodics Drugs, by Indication USD Million (2015-2020)
  • Table 181. Mexico Antispasmodics Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 182. Mexico Antispasmodics Drugs, by End User USD Million (2015-2020)
  • Table 183. Company Basic Information, Sales Area and Its Competitors
  • Table 184. Company Basic Information, Sales Area and Its Competitors
  • Table 185. Company Basic Information, Sales Area and Its Competitors
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Antispasmodics Drugs: by Type(USD Million)
  • Table 194. Antispasmodics Drugs Dicyclomine Hydrochloride , by Region USD Million (2021-2026)
  • Table 195. Antispasmodics Drugs Loperamide Hydrochloride , by Region USD Million (2021-2026)
  • Table 196. Antispasmodics Drugs Others , by Region USD Million (2021-2026)
  • Table 197. Antispasmodics Drugs: by Route of Administration(USD Million)
  • Table 198. Antispasmodics Drugs Oral , by Region USD Million (2021-2026)
  • Table 199. Antispasmodics Drugs Injectable , by Region USD Million (2021-2026)
  • Table 200. Antispasmodics Drugs Sublingual , by Region USD Million (2021-2026)
  • Table 201. Antispasmodics Drugs Others , by Region USD Million (2021-2026)
  • Table 202. Antispasmodics Drugs: by Indication(USD Million)
  • Table 203. Antispasmodics Drugs Irritable Bowel Syndrome , by Region USD Million (2021-2026)
  • Table 204. Antispasmodics Drugs Stomach Cramps , by Region USD Million (2021-2026)
  • Table 205. Antispasmodics Drugs Others , by Region USD Million (2021-2026)
  • Table 206. Antispasmodics Drugs: by Distribution Channel(USD Million)
  • Table 207. Antispasmodics Drugs Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 208. Antispasmodics Drugs Online Pharmacy , by Region USD Million (2021-2026)
  • Table 209. Antispasmodics Drugs Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 210. Antispasmodics Drugs: by End User(USD Million)
  • Table 211. Antispasmodics Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 212. Antispasmodics Drugs Homecare , by Region USD Million (2021-2026)
  • Table 213. Antispasmodics Drugs Speciality Centres , by Region USD Million (2021-2026)
  • Table 214. Antispasmodics Drugs Others , by Region USD Million (2021-2026)
  • Table 215. South America Antispasmodics Drugs, by Country USD Million (2021-2026)
  • Table 216. South America Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 217. South America Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 218. South America Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 219. South America Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 220. South America Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 221. Brazil Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 222. Brazil Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 223. Brazil Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 224. Brazil Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 225. Brazil Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 226. Argentina Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 227. Argentina Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 228. Argentina Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 229. Argentina Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 230. Argentina Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 231. Rest of South America Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 232. Rest of South America Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 233. Rest of South America Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 234. Rest of South America Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 235. Rest of South America Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 236. Asia Pacific Antispasmodics Drugs, by Country USD Million (2021-2026)
  • Table 237. Asia Pacific Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 238. Asia Pacific Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 239. Asia Pacific Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 240. Asia Pacific Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 241. Asia Pacific Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 242. China Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 243. China Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 244. China Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 245. China Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 246. China Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 247. Japan Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 248. Japan Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 249. Japan Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 250. Japan Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 251. Japan Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 252. India Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 253. India Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 254. India Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 255. India Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 256. India Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 257. South Korea Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 258. South Korea Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 259. South Korea Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 260. South Korea Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 261. South Korea Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 262. Singapore Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 263. Singapore Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 264. Singapore Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 265. Singapore Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 266. Singapore Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 267. Australia Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 268. Australia Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 269. Australia Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 270. Australia Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 271. Australia Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 272. Rest of Asia-Pacific Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 273. Rest of Asia-Pacific Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 274. Rest of Asia-Pacific Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 275. Rest of Asia-Pacific Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 276. Rest of Asia-Pacific Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 277. Europe Antispasmodics Drugs, by Country USD Million (2021-2026)
  • Table 278. Europe Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 279. Europe Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 280. Europe Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 281. Europe Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 282. Europe Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 283. Germany Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 284. Germany Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 285. Germany Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 286. Germany Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 287. Germany Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 288. France Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 289. France Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 290. France Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 291. France Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 292. France Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 293. Italy Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 294. Italy Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 295. Italy Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 296. Italy Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 297. Italy Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 298. United Kingdom Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 299. United Kingdom Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 300. United Kingdom Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 301. United Kingdom Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 302. United Kingdom Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 303. Netherlands Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 304. Netherlands Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 305. Netherlands Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 306. Netherlands Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 307. Netherlands Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 308. Spain Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 309. Spain Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 310. Spain Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 311. Spain Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 312. Spain Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 313. Rest of Europe Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 314. Rest of Europe Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 315. Rest of Europe Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 316. Rest of Europe Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 317. Rest of Europe Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 318. MEA Antispasmodics Drugs, by Country USD Million (2021-2026)
  • Table 319. MEA Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 320. MEA Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 321. MEA Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 322. MEA Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 323. MEA Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 324. Saudi Arabia Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 325. Saudi Arabia Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 326. Saudi Arabia Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 327. Saudi Arabia Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 328. Saudi Arabia Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 329. Turkey Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 330. Turkey Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 331. Turkey Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 332. Turkey Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 333. Turkey Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 334. Israel Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 335. Israel Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 336. Israel Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 337. Israel Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 338. Israel Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 339. United Arab Emirates Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 340. United Arab Emirates Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 341. United Arab Emirates Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 342. United Arab Emirates Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 343. United Arab Emirates Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 344. South Africa Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 345. South Africa Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 346. South Africa Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 347. South Africa Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 348. South Africa Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 349. Rest of Africa Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 350. Rest of Africa Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 351. Rest of Africa Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 352. Rest of Africa Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 353. Rest of Africa Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 354. North America Antispasmodics Drugs, by Country USD Million (2021-2026)
  • Table 355. North America Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 356. North America Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 357. North America Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 358. North America Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 359. North America Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 360. United States Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 361. United States Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 362. United States Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 363. United States Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 364. United States Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 365. Canada Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 366. Canada Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 367. Canada Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 368. Canada Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 369. Canada Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 370. Mexico Antispasmodics Drugs, by Type USD Million (2021-2026)
  • Table 371. Mexico Antispasmodics Drugs, by Route of Administration USD Million (2021-2026)
  • Table 372. Mexico Antispasmodics Drugs, by Indication USD Million (2021-2026)
  • Table 373. Mexico Antispasmodics Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 374. Mexico Antispasmodics Drugs, by End User USD Million (2021-2026)
  • Table 375. Research Programs/Design for This Report
  • Table 376. Key Data Information from Secondary Sources
  • Table 377. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antispasmodics Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Antispasmodics Drugs: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Antispasmodics Drugs: by Indication USD Million (2015-2020)
  • Figure 7. Global Antispasmodics Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global Antispasmodics Drugs: by End User USD Million (2015-2020)
  • Figure 9. South America Antispasmodics Drugs Share (%), by Country
  • Figure 10. Asia Pacific Antispasmodics Drugs Share (%), by Country
  • Figure 11. Europe Antispasmodics Drugs Share (%), by Country
  • Figure 12. MEA Antispasmodics Drugs Share (%), by Country
  • Figure 13. North America Antispasmodics Drugs Share (%), by Country
  • Figure 14. Global Antispasmodics Drugs share by Players 2020 (%)
  • Figure 15. Global Antispasmodics Drugs share by Players (Top 3) 2020(%)
  • Figure 16. Global Antispasmodics Drugs share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 19. Allergan (Ireland) Revenue: by Geography 2020
  • Figure 20. Hikma Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Hikma Pharmaceuticals (United Kingdom) Revenue: by Geography 2020
  • Figure 22. Lannett (United States) Revenue, Net Income and Gross profit
  • Figure 23. Lannett (United States) Revenue: by Geography 2020
  • Figure 24. Mylan N.V.(United States) Revenue, Net Income and Gross profit
  • Figure 25. Mylan N.V.(United States) Revenue: by Geography 2020
  • Figure 26. Nexus Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 27. Nexus Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 28. Akorn Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 29. Akorn Incorporated (United States) Revenue: by Geography 2020
  • Figure 30. Aurobindo Pharma (India) Revenue, Net Income and Gross profit
  • Figure 31. Aurobindo Pharma (India) Revenue: by Geography 2020
  • Figure 32. Daiichi Sankyo, Inc (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Daiichi Sankyo, Inc (Japan) Revenue: by Geography 2020
  • Figure 34. Fresenius Kabi Ag (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Fresenius Kabi Ag (Germany) Revenue: by Geography 2020
  • Figure 36. Shanghai Fosun Pharmaceutical & Co., Ltd (China) Revenue, Net Income and Gross profit
  • Figure 37. Shanghai Fosun Pharmaceutical & Co., Ltd (China) Revenue: by Geography 2020
  • Figure 38. Global Antispasmodics Drugs: by Type USD Million (2021-2026)
  • Figure 39. Global Antispasmodics Drugs: by Route of Administration USD Million (2021-2026)
  • Figure 40. Global Antispasmodics Drugs: by Indication USD Million (2021-2026)
  • Figure 41. Global Antispasmodics Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 42. Global Antispasmodics Drugs: by End User USD Million (2021-2026)
  • Figure 43. South America Antispasmodics Drugs Share (%), by Country
  • Figure 44. Asia Pacific Antispasmodics Drugs Share (%), by Country
  • Figure 45. Europe Antispasmodics Drugs Share (%), by Country
  • Figure 46. MEA Antispasmodics Drugs Share (%), by Country
  • Figure 47. North America Antispasmodics Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Allergan (Ireland)
  • Hikma Pharmaceuticals (United Kingdom)
  • Lannett (United States)
  • Mylan N.V.(United States)
  • Nexus Pharmaceuticals (United States)
  • Akorn Incorporated (United States)
  • Aurobindo Pharma (India)
  • Daiichi Sankyo, Inc (Japan)
  • Fresenius Kabi Ag (Germany)
  • Shanghai Fosun Pharmaceutical & Co., Ltd (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation